2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro- manufacturers
- GSK-2793660
-
- $1980.00
-
2026-07-27
- CAS:1613458-70-0
- Purity:
- Supply Ability: 10g
- GSK-2793660
-
- $1980.00
-
2026-07-27
- CAS:1613458-70-0
- Purity:
- Supply Ability: 10g
- GSK-2793660
-
- $1980.00
-
2025-08-22
- CAS:1613458-70-0
- Purity:
- Supply Ability: 10g
|
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro- Basic information |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro- Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro- Usage And Synthesis |
| Uses | GSK-2793660 (free base) is an oral, irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 (free base) can be used for the research of bronchiectasis[1][2]. | | in vivo | GSK-2793660 (free base) is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1]. | | IC 50 | Cathepsin C | | References | [1] Szczeniak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016 Feb 5;81(3):1057-74. DOI:10.1021/acs.joc.5b02628 [2] Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820. DOI:10.1111/bcp.13398 |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro- Preparation Products And Raw materials |
|